Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:14 AM
Ignite Modification Date:
2025-12-25 @ 3:14 AM
NCT ID:
NCT02623205
Eligibility Criteria:
Inclusion Criteria:
1. Age range: over 18 years old
2. Capacity to consent
3. Diagnosis of MDD and suffering from a major depressive episode
4. Score of at least 22 on the MADRS
Exclusion Criteria:
1. Significant active physical illness, particularly those that may affect the brain
2. Need for use of medication during the study that will interact with the study medication. Need to start medication that will affect study results (anti epileptics, antidepressants, beta blockers, medications with serotonergic or GABAergic modes of action)
3. Patients considered at significant risk for suicide
4. Patient is unlikely to be able to tolerate medication washout or the \~3 week interval (5 for fluoxetine) following washout (drug free period). Medication washouts will be supervised by a study physician.
5. For females: Pregnancy, currently lactating; planning to conceive during the course of study participation, or abortion in the past two months.
6. Coumadin treatment within 10 days of PET scanning
7. Any MRI contraindications, including metal implants, pacemaker, metal prostheses, orthodontic appliances, or presence of shrapnel that are contraindicated for MRI.
8. Bipolar Disorder
9. Current psychosis
10. High potential for excessive drug/alcohol use during the treatment period (excluding nicotine or cannabis)
11. Currently taking effective antidepressant
12. Currently taking an effective antidepressant
13. Prior intolerance escitalopram (ESC) for ≥ 4 weeks taking ≥ ⅔ Physician's Desk Reference (PDR) maximal dose
14. Significant neurological deficits
15. Electroconvulsive Therapy (ECT) within the past 6 months
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02623205
Study Brief:
Protocol Section:
NCT02623205